5-(azetidin-3-yl)-3-chloro-1-(3-difluoromethoxyphenylsulfonyl)-1H-indole | 1063994-40-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 5-(azetidin-3-yl)-3-chloro-1-(3-difluoromethoxyphenylsulfonyl)-1H-indole
• 英文别名: 5-(Azetidin-3-yl)-3-chloro-1-[3-(difluoromethoxy)phenyl]sulfonylindole
• CAS: 1063994-40-0
• 化学式: C₁₈H₁₅ClF₂N₂O₃S
• 分子量: 412.845
• InChiKey: KWCBAORVSLWTIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  68.7
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR
  申请人：Schultz, SR. Thomas

  公开号：US20100137280A1

  公开（公告）日：2010-06-03

  The present invention relates to compounds of formula (I) wherein A is C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, C 1 -C 6 -hydroxyalkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -halo-alkenyl, C 3 -C 6 -cycloalkyl, aryl-C 1 -C 4 -alkyl, aryl-C 2 -C 4 -alkenyl, aryl or hetaryl, is a single or double bond; X 1 and X 2 are N, CR x1 , NR x2 , or CR x3 R x4 ; R x1 , R x3 and R x4 are H, halogen, CN, NO 2 , C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkylcarbonyl, etc. or two geminal radicals R x3 and R x4 together with the carbon atom to which they are bound may form a carbonyl group or a 3- to 6-membered carbocyclic or heterocyclic spiro-annulated ring; R x2 is hydrogen, C 1 -C 6 -alkyl, C 1 -C 6 -alkylcarbonyl, C 1 -C 6 -haloalkyl, etc.; or two vicinal radicals R x1 , R x2 , R x3 or R x4 together with X 1 and X 2 form a five- or six-membered carbocyclic or heterocyclic fused ring; Y 1 , Y 2 and Y 3 are N or CR y ; R y is H, halogen, CN, NO 2 , C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkylcarbonyl, C 1 -C 6 -haloalkyl, etc.; wherein a maximum of 3 of the radicals X 1 , X 2 , Y 1 , Y 2 and Y 3 are selected from NR x1 and N; R 1 is hydrogen, C 1 -C 6 -alkyl, C 1 -C 6 -hydroxyalkyl, C 1 -C 6 -haloalkyl, etc.; R 2 is C 1 -C 4 -alkyl or C 1 -C 4 -haloalkyl; n is 0, 1 or 2; physiologically tolerated acid addition salts and the N-oxides thereof, pharmaceutical composition comprising them, a method for treating medical disorders selected from diseases of the central nervous system, addiction diseases or obesity, said method comprising administering an effective amount of such compounds to a subject in need and the use of such a compound for preparing a pharmaceutical compositions.

  本发明涉及式（I）的化合物，其中A为C1-C6烷基，C1-C6卤代烷基，C1-C6羟基烷基，C2-C6烯基，C2-C6卤代烯基，C3-C6环烷基，芳基-C1-C4-烷基，芳基-C2-C4-烯基，芳基或杂芳基，为单键或双键；X1和X2为N，CRx1，NRx2或CRx3Rx4；Rx1，Rx3和Rx4为H，卤素，CN，NO2，C1-C6烷基，C1-C6烷氧基，C1-C6烷基羰基等，或者两个同位素基团Rx3和Rx4与它们所连接的碳原子一起可以形成一个羰基团或一个3-至6-环碳环或杂环螺旋环；Rx2为氢，C1-C6烷基，C1-C6烷基羰基，C1-C6卤代烷基等；或者两个邻位基团Rx1，Rx2，Rx3或Rx4与X1和X2一起形成一个五元或六元碳环或杂环融合环；Y1，Y2和Y3为N或CRy；Ry为H，卤素，CN， ，C1-C6烷基，C1-C6烷氧基，C1-C6烷基羰基，C1-C6卤代烷基等；其中最多3个基团X1，X2，Y1，Y2和Y3从NRx1和N中选择；R1为氢，C1-C6烷基，C1-C6羟基烷基，C1-C6卤代烷基等；R2为C1-C4烷基或C1-C4卤代烷基；n为0，1或2；生理上耐受的酸盐和其N-氧化物，包含它们的制药组合物，一种用于治疗中枢神经系统疾病、成瘾疾病或肥胖症的医疗障碍的方法，该方法包括向需要的受体中给予这种化合物的有效量以及使用这种化合物制备制药组合物。
• US8507469B2
  申请人：——

  公开号：US8507469B2

  公开（公告）日：2013-08-13